Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
- Conditions
- Chronic Migraine
- Interventions
- Registration Number
- NCT03855137
- Lead Sponsor
- Allergan
- Brief Summary
This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 778
-
At least a 1-year history of chronic migraine (CM) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3), 2018
-
Age of the participant at the time of migraine onset < 50 years
-
Confirmation of headache/migraine headache day frequency as follows:
- History of, on average, ≥ 15 headache days per month in the 3 months prior to Visit 1 in the opinion of the investigator AND
- >=15 headache days during the 4-week screening/baseline period per the electronic diary (eDiary) AND
- >=8 days during the 4-week screening/baseline period that qualify as being a migraine day per the eDiary
-
Participants must be using a medically acceptable and effective method of birth control during the course of the entire study
- Has a history of migraine, accompanied by diplopia or decreased level of consciousness, or retinal migraine
- Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy
- History of an inadequate response to > 4 medications (2 of which have different mechanisms of action) prescribed for the prevention of migraine
- Woman is pregnant, planning to become pregnant during the course of the study, or currently lactating. Women of childbearing potential must have a negative urine pregnancy test at Visit 1 and Visit 2.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Atogepant 30 mg BID Atogepant 30 mg Participants received atogepant 30 mg tablet, orally, BID and atogepant-matching placebo tablets orally, BID for up to 12 weeks in a DB treatment period. Atogepant 60 mg QD Atogepant 60 mg Participants received atogepant 60 mg, orally, once daily (QD) along with atogepant-matching placebo 30 mg as morning dose followed by atogepant-matching placebo 30 mg and 60 mg as evening doses for up to 12 weeks in a DB treatment period. Placebo Placebo Participants received atogepant-matching placebo tablets, orally, twice daily (BID) for 12 weeks in a double-blind (DB) treatment period. Atogepant 30 mg BID Placebo Participants received atogepant 30 mg tablet, orally, BID and atogepant-matching placebo tablets orally, BID for up to 12 weeks in a DB treatment period. Atogepant 60 mg QD Placebo Participants received atogepant 60 mg, orally, once daily (QD) along with atogepant-matching placebo 30 mg as morning dose followed by atogepant-matching placebo 30 mg and 60 mg as evening doses for up to 12 weeks in a DB treatment period.
- Primary Outcome Measures
Name Time Method Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population Baseline to Week 12 Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days were defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. A contrast from Mixed-effects model for repeated measures (MMRM) was used to obtain the average treatment effects across the 12-week treatment period.
Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in Off-Treatment Hypothetical Estimand Population Baseline to Week 12 Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days were defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. A contrast from Mixed-effects model for repeated measures (MMRM) was used to obtain the average treatment effects across the 12-week treatment period.
- Secondary Outcome Measures
Name Time Method Change From Baseline in Mean Monthly Acute Medication Use Days Across 12-Week Treatment Period in Off-treatment Hypothetical Estimand Population Baseline to Week 12 An acute medication use day is defined as any day on which a participant reports, per eDiary, the intake of allowed medication(s) to treat an acute migraine. The monthly (4-week) acute medication use days were defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. A negative change from Baseline indicates improvement. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.
Change From Baseline in Mean Monthly Headache Days Across 12-Week Treatment Period in Off-Treatment Hypothetical Estimand Population Baseline to Week 12 Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache pain lasting 2 hours or longer unless an acute headache medication was used after the start of the headache. The monthly (4-week) headache days were defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of headache days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.
Change From Baseline in Mean Monthly Headache Days Across 12-Week Treatment Period in mITT Population Baseline to Week 12 Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache pain lasting 2 hours or longer unless an acute headache medication was used after the start of the headache. The monthly (4-week) headache days were defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of headache days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.
Percentage of Participants With at Least a 50% Reduction in 3-Month Average of Monthly Migraine Days in Off-Treatment Hypothetical Estimand Population Baseline to Week 12 Data is reported for 50% responders averaged at each 4-week period. 50% responders are participants with at least a 50 percent reduction from baseline in 3-month average of monthly migraine days. Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days is equal to total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28. The values are rounded off to the first decimal value.
Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the AIM-D Across 12-Week Treatment Period in mITT Population Baseline to Week 12 The AIM-D is a 11-item patient-reported outcome (PRO) measure that assesses the impact of migraine on the performance of daily activities which include, 7 items: difficulty with household chores, errands, leisure activities at home, leisure or social activities outside the home, strenuous physical activities, concentrating, and thinking clearly and physical impairment; 4 items: difficulty walking, moving body, bending forward, moving head using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw performance of daily activities domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden). A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.
Change From Baseline in Mean Monthly Acute Medication Use Days Across 12-Week Treatment Period in mITT Population Baseline to Week 12 An acute medication use day is defined as any day on which a participant reports, per eDiary, the intake of allowed medication(s) to treat an acute migraine. The monthly (4-week) acute medication use days were defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. A negative change from Baseline indicates improvement. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.
Percentage of Participants With at Least a 50% Reduction in 3-Month Average of Monthly Migraine Days in mITT Population Baseline to Week 12 Data is reported for 50% responders averaged at each 4-week period. 50% responders are participants with at least a 50 percent reduction from baseline in 3-month average of monthly migraine days. Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days is equal to total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28. The values are rounded off to the first decimal value.
Change From Baseline in Migraine Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score at Week 12 in Off-Treatment Hypothetical Estimand Population At Week 12 The MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality of life impairments attributed to migraine in the past 4 weeks. It is divided into 3 domains: Role Function Restrictive (question numbers 1-7, score ranges 7 to 42) assesses how migraines limit one's daily social and work-related activities; Role Function Preventive (question numbers 8-11, score ranges 4 to 24) assesses how migraines prevent these activities; and the Emotional Function (question numbers 12-14, score ranges 3 to 18) domain assesses the emotions associated with migraines. Participants respond to items using a 6-point scale ranging from none of the time to all of the time. Raw dimension scores are computed as a sum of item responses and rescaled to a 0 to 100 scale, where higher scores indicate better quality of life. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.
Change From Baseline in Mean Monthly Physical Impairment Domain Score of the AIM-D Across 12-Week Treatment Period in mITT Population Baseline to Week 12 The AIM-D is a 11-item PRO measure that assesses the impact of migraine on the performance of daily activities which includes 7 items: difficulty with household chores, errands, leisure activities at home, leisure or social activities outside the home, strenuous physical activities, concentrating, and thinking clearly and physical impairment; 4 items: difficulty walking, moving body, bending forward, moving head using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw physical impairment domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden). A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.
Change From Baseline in the Headache Impact Test (HIT-6) Total Score at Week 12 in Off-Treatment Hypothetical Estimand Population At Week 12 HIT-6 is a 6-question assessment used to measure the impact headaches have on a participant's ability to function on the job, at school, at home, and in social situations. It assesses the effect that headaches have on normal daily life and the participant's ability to function. Responses are based on frequency using a 5-point scale ranging from "never" to "always." The HIT-6 total score, which ranges from 36 to 78, is the sum of the responses - each of which is assigned a score ranging from 6 points (never) to 13 points (always). MMRM was used for the analyses.
Trial Locations
- Locations (150)
AP-HM - Hopital de la Timone /ID# 236285
🇫🇷Marseille CEDEX 05, Bouches-du-Rhone, France
DiscoveResearch, Inc /ID# 236274
🇺🇸Bryan, Texas, United States
Abington Neurological Associates - Abington /ID# 236258
🇺🇸Abington, Pennsylvania, United States
Texas Neurology /ID# 236359
🇺🇸Dallas, Texas, United States
Higashi Sapporo Neurology and Neurosurgery Clinic /ID# 234549
🇯🇵Sapporo-shi, Hokkaido, Japan
Saitama Medical University Hospital /ID# 237019
🇯🇵Iruma-gun, Saitama, Japan
Puget Sound Neurology /ID# 236321
🇺🇸Tacoma, Washington, United States
Vancouver Island Health Authority /ID# 238053
🇨🇦Victoria, British Columbia, Canada
Ottawa Headache Centre Research Inc /ID# 236432
🇨🇦Ottawa, Ontario, Canada
MedStar Georgetown Neurology /ID# 236324
🇺🇸McLean, Virginia, United States
Chinese PLA General Hospital /ID# 238237
🇨🇳Beijing, Beijing, China
BRAIN-SOULTHERAPY s.r.o. /ID# 236380
🇨🇿Kladno, Czechia
NEUROHK s.r.o. /ID# 236290
🇨🇿Hradec Kralove, Czechia
Dent Neurosciences Research Center, Inc. /ID# 237040
🇺🇸Amherst, New York, United States
Headache Wellness Center /ID# 236431
🇺🇸Greensboro, North Carolina, United States
Hubei General Hospital /ID# 236486
🇨🇳Wuhan, Hebei, China
Sentara Neurology Specialists - Virginia Beach /ID# 234349
🇺🇸Virginia Beach, Virginia, United States
The Royal Melbourne Hospital /ID# 236859
🇦🇺Parkville, Victoria, Australia
CHAMP Clinic /ID# 236252
🇨🇦Calgary, Alberta, Canada
WR-ClinSearch /ID# 238288
🇺🇸Chattanooga, Tennessee, United States
Royal North Shore Hospital /ID# 237008
🇦🇺St Leonards, New South Wales, Australia
Praxis Dr. Gendolla /ID# 236311
🇩🇪Essen, Germany
CCR Czech a.s /ID# 236249
🇨🇿Prague 4, Czechia
CCR Prague s.r.o. /ID# 236250
🇨🇿Praha, Czechia
Raleigh Neurology Associates /ID# 237141
🇺🇸Raleigh, North Carolina, United States
CCR Ostrava, s.r.o. /ID# 234291
🇨🇿Ostrava, Czechia
Konan Medical Center /ID# 236230
🇯🇵Kobe-shi, Hyogo, Japan
Atsuchi Neurosurgical Hospital /ID# 234779
🇯🇵Kagoshima-shi, Kagoshima, Japan
Nagaseki Headache Clinic /ID# 234561
🇯🇵Kai-shi, Yamanashi, Japan
DOI Internal Medicine-Neurology Clinic /ID# 234562
🇯🇵Hiroshima, Japan
Hiroshima Neurology Clinic /ID# 234563
🇯🇵Hiroshima, Japan
Dongtan Sacred Heart Hospital /ID# 238097
🇰🇷Hwaseong, Gyeonggido, Korea, Republic of
CLINTRIAL s.r.o. /ID# 237793
🇨🇿Prague 10, Czechia
Vitos Orthopaedische Klinik Kassel gemeinnuetzige GmbH /ID# 236723
🇩🇪Kassel, Germany
Nowon Eulji Medical Center, Eulji University /ID# 236306
🇰🇷Seoul, Korea, Republic of
NeuroMed Zlin s.r.o. /ID# 236416
🇨🇿Zlin, Czechia
CHU Gabriel Montpied /ID# 237323
🇫🇷Clermont Ferrand, France
Takanoko Hospital /ID# 234564
🇯🇵Matsuyama-shi, Ehime, Japan
Saitama Neuropsychiatric Institute /Id# 234550
🇯🇵Saitama-shi, Saitama, Japan
Tokyo Headache Clinic /ID# 234555
🇯🇵Shibuya-ku, Tokyo, Japan
CTC North GmbH & Co. KG /ID# 236328
🇩🇪Hamburg, Germany
FORBELI s.r.o. /ID# 236427
🇨🇿Prague, Czechia
Keio University Hospital /ID# 237210
🇯🇵Shinjuku-ku, Tokyo, Japan
Japanese Red Cross Shizuoka Hospital /ID# 234372
🇯🇵Shizuoka-shi, Shizuoka, Japan
Specjalistyczne Gabinety Sp. z o.o. /ID# 236348
🇵🇱Krakow, Malopolskie, Poland
State Autonomous Healthcare Institution Republican Clinical Neurology Centre /ID# 236354
🇷🇺Kazan, Tatarstan, Respublika, Russian Federation
Universitaetsklinikum Essen /ID# 237209
🇩🇪Essen, Germany
Schmerzklinik Kiel /ID# 236444
🇩🇪Kiel, Germany
Hospital Clinico Universitario de Valencia /ID# 237400
🇪🇸Valencia, Spain
Pusan National University Hospital /ID# 237120
🇰🇷Busan, Korea, Republic of
Tanaka Neurosurgical clinic /ID# 234760
🇯🇵Kagoshima, Japan
NZOZ Vitamed /ID# 237041
🇵🇱Bydgoszcz, Kujawsko-pomorskie, Poland
Centrum Medyczne Pratia Gdynia /ID# 237077
🇵🇱Gdynia, Pomorskie, Poland
Solumed Centrum Medyczne /ID# 236452
🇵🇱Poznan, Wielkopolskie, Poland
Central Clinical Hospital RZHD Medicine /ID# 237024
🇷🇺Moscow, Russian Federation
Tatsuoka Neurology Clinic /ID# 234782
🇯🇵Kyoto, Japan
Silmedic Sp. z o.o. /ID# 237343
🇵🇱Katowice, Slaskie, Poland
EuroMedis sp. z o.o. /ID# 236417
🇵🇱Szczecin, Zachodniopomorskie, Poland
Hospital Universitario Vall d'Hebron /ID# 236467
🇪🇸Barcelona, Spain
Yonsei University Health System Severance Hospital /ID# 237839
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Centrum Leczenia Padaczki i Migreny /ID# 236386
🇵🇱Krakow, Malopolskie, Poland
CLINICA UNIVERSIDAD DE NAVARRA-Pamplona /ID# 237645
🇪🇸Pamplona, Navarra, Spain
Hospital Universitario Virgen del Rocio /ID# 237106
🇪🇸Sevilla, Spain
University Headache Clinic /ID# 236371
🇷🇺Moscow, Russian Federation
Clinics Chaika /ID# 236394
🇷🇺Moscow, Russian Federation
Walton Centre /ID# 236468
🇬🇧Liverpool, United Kingdom
Guangzhou First People's Hospital /ID# 236510
🇨🇳Guangzhou, Guangdong, China
Peking University Third Hospital /ID# 238150
🇨🇳Beijing, Beijing, China
The First Affiliated Hospital of Zhengzhou University /ID# 237025
🇨🇳Zhengzhou, Henan, China
The Second Affiliated Hospital of Guangzhou Medical University /ID# 238133
🇨🇳Guangzhou, Guangdong, China
Jiangsu Province Hospital /ID# 237846
🇨🇳Nanjing, Jiangsu, China
The Second Hospital of Jilin University /ID# 236520
🇨🇳Changchun, Jilin, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 237847
🇨🇳Shanghai, Shanghai, China
The Second Hospital of Shanxi Medical University /ID# 236529
🇨🇳Taiyuan, Shanxi, China
The second Affiliated hospital of Zhejiang University school of Medicine /ID# 238260
🇨🇳Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine /ID# 236500
🇨🇳Hangzhou, Zhejiang, China
The Second Hospital of Soochow University /ID# 234296
🇨🇳Suzhou, China
Tianjin Huanhu Hospital (THH) /ID# 236524
🇨🇳Tianjin, China
Beijing Friendship Hospital /ID# 237264
🇨🇳Beijing, China
Tongji Hospital Tongji Medical College of HUST /ID# 237835
🇨🇳Wuhan, China
Montreal Neurological Institut /ID# 236329
🇨🇦Montreal, Quebec, Canada
Fujitsu Clinic /ID# 237443
🇯🇵Kawasaki-shi, Kanagawa, Japan
Umenotsuji Clinic /ID# 234495
🇯🇵Kochi-shi, Kochi, Japan
Niwa Family Clinic /ID# 234552
🇯🇵Chofu-shi, Tokyo, Japan
CH Annecy Genevois Site Annecy /ID# 236385
🇫🇷PRINGY cedex, Haute-Savoie, France
Albany Medical Center Rheumatology /ID# 236540
🇺🇸Albany, New York, United States
Barrow Neuro Institute /ID# 236776
🇺🇸Phoenix, Arizona, United States
J. Lewis Research, Inc. / Foothill Family Clinic /ID# 236395
🇺🇸Salt Lake City, Utah, United States
J. Lewis Research, Inc. Foothill Family Clinic South /ID# 236297
🇺🇸Salt Lake City, Utah, United States
Stetson-University of Cincinnati /ID# 236453
🇺🇸Cincinnati, Ohio, United States
Preferred Primary Care Physicians, Inc. /ID# 236439
🇺🇸Pittsburgh, Pennsylvania, United States
Highland Clinical Research /ID# 237816
🇺🇸Salt Lake City, Utah, United States
California Headache and Balance Center /ID# 236246
🇺🇸Fresno, California, United States
Wr-Pri Llc /Id# 236008
🇺🇸Los Alamitos, California, United States
Baptist Health Center for Clinical Research /ID# 237361
🇺🇸Little Rock, Arkansas, United States
Pharmacology Research Institute (PRI) - Newport Beach (Wake) /ID# 237692
🇺🇸Newport Beach, California, United States
Schuster Medical Research Institute /ID# 236447
🇺🇸Sherman Oaks, California, United States
Alpine Clinical Research Center /ID# 234346
🇺🇸Boulder, Colorado, United States
Accel Research Sites - Tampa Clinical Research Unit /ID# 237485
🇺🇸Tampa, Florida, United States
George Washington University Medical Faculty Associates /ID# 238011
🇺🇸Washington, District of Columbia, United States
Premiere Research Institute - Palm Beach /ID# 238192
🇺🇸West Palm Beach, Florida, United States
NeuroTrials Research Inc. /ID# 237364
🇺🇸Atlanta, Georgia, United States
Josephson-Wallack-Munshower Neurology - NE /ID# 238234
🇺🇸Indianapolis, Indiana, United States
Collective Medical Research /ID# 236400
🇺🇸Prairie Village, Kansas, United States
Ochsner Clinic Foundation /ID# 236543
🇺🇸Covington, Louisiana, United States
Beth Israel Deaconess Medical Center /ID# 237540
🇺🇸Boston, Massachusetts, United States
Clinical Research Institute, Inc /ID# 238299
🇺🇸Minneapolis, Minnesota, United States
BTC of New Bedford /ID# 236384
🇺🇸New Bedford, Massachusetts, United States
Headache Neurology Research Institute /ID# 236464
🇺🇸Ridgeland, Mississippi, United States
Nevada Headache Institute /ID# 236420
🇺🇸Las Vegas, Nevada, United States
Albuquerque Clinical Trials, Inc /ID# 236853
🇺🇸Albuquerque, New Mexico, United States
Dartmouth-Hitchcock Medical Center /ID# 237444
🇺🇸Lebanon, New Hampshire, United States
Thomayerova nemocnice /ID# 237175
🇨🇿Praha, Czechia
Charite Universitaetsklinikum Berlin - Campus Virchow /ID# 237256
🇩🇪Berlin, Germany
Tokai University Hospital /ID# 237595
🇯🇵Isehara-shi, Kanagawa, Japan
Sendai Headache and Neurology Clinic Medical Corporation /ID# 234496
🇯🇵Sendai-shi, Miyagi, Japan
Samsung Medical Center /ID# 237785
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital /ID# 237786
🇰🇷Seoul, Korea, Republic of
Tainan Sin Lau Hospital /ID# 236358
🇨🇳Tainan City, Taiwan
Hospital Universitario y Politecnico La Fe /ID# 237087
🇪🇸Valencia, Spain
Chi-Mei Medical Center /ID# 236724
🇨🇳Tainan, Taiwan
Hospital Clinico Universitario de Valladolid /ID# 234406
🇪🇸Valladolid, Spain
Kuang-Tien General Hospital /ID# 236309
🇨🇳Taichung City, Taiwan
Hospital Clinico Universitario Lozano Blesa /ID# 237373
🇪🇸Zaragoza, Spain
Taipei Veterans General Hosp /ID# 237236
🇨🇳Taipei City, Taiwan
Tri-Service General Hospital /ID# 237657
🇨🇳Taipei City, Taiwan
King's College Hospital NHS Foundation Trust /ID# 236301
🇬🇧London, United Kingdom
Rigshospitalet Glostrup /ID# 236411
🇩🇰Glostrup, Hovedstaden, Denmark
Azienda Ospedaliera Universitaria Consorziale Policlinico /ID# 237492
🇮🇹Bari, Italy
Azienda Ospedaliero Universitaria Careggi /ID# 237598
🇮🇹Florence, Italy
Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 237291
🇮🇹Milan, Italy
AOU Universita degli Studi della Campania Luigi Vanvitelli /ID# 236361
🇮🇹Napoli, Italy
Universita di Pavia /ID# 236363
🇮🇹Pavia, Italy
IRCCS San Raffaele Pisana /ID# 236552
🇮🇹Rome, Italy
Stortorgets Neurologmottagning /ID# 236454
🇸🇪Helsingborg, Sweden
Hôpital Pierre Wertheimer /ID# 236969
🇫🇷Bron, France
Kangbuk Samsung Hospital /ID# 237754
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
LMU Klinikum Campus Grosshadern /ID# 236293
🇩🇪München, Germany
Hospital Clínico Universitario de Santiago-CHUS /ID# 237623
🇪🇸Santiago de Compostela, A Coruna, Spain
University of Texas Southwestern Medical Center /ID# 236941
🇺🇸Dallas, Texas, United States
Accel Research Sites - St Petersburg Clinical Research Unit /ID# 237161
🇺🇸Saint Petersburg, Florida, United States
Northwest Clinical Research Center /ID# 237581
🇺🇸Bellevue, Washington, United States
Clinique des cephalees de Montreal /ID# 236266
🇨🇦Montreal, Quebec, Canada
Fukuiken Saiseikai Hospital /ID# 236794
🇯🇵Fukui-shi, Fukui, Japan
Dokkyo Medical University Hospital /ID# 236810
🇯🇵Shimotsuga-gun, Tochigi, Japan
Tominaga Hospital /ID# 234781
🇯🇵Osaka, Japan
Shinagawa Strings Clinic /ID# 234780
🇯🇵Tokyo, Japan
Indywidualna Praktyka Lekarska dr hab. med. Anna Szczepanska-Szerej /ID# 236289
🇵🇱Lublin, Lubelskie, Poland
Kazan State Medical University /ID# 236298
🇷🇺Kazan, Tatarstan, Respublika, Russian Federation
Clinical Neuroscience Solutions - Memphis /ID# 237478
🇺🇸Memphis, Tennessee, United States